SCHEMBL952273

SCHEMBL952273

O=C(NCc1ccncc1)c1n[nH]c2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.68
MAPK10 P53779 1/20 0.68
HSD17B10 Q99714 1/20 0.68
FLT1 P17948 1/20 0.66
KDR P35968 1/20 0.66
SMN1; SMN2 Q16637 4/20 0.64
NPC1 O15118 4/20 0.64
RAB9A P51151 4/20 0.64
ALDH1A1 P00352 2/20 0.64
GAA P10253 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
YTHDC1 Q96MU7 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
MAPK1 P28482 2/20 0.58
MAPK3 P27361 1/20 0.58
NAMPT P43490 1/20 0.58
CCNA2 P20248 1/20 0.56
CDK2 P24941 1/20 0.56
FLT3 P36888 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL952028 0.90 SMN1; SMN2 (0.77) KDM4EMAPK10HSD17B10SMN1; SMN2NPC1
SCHEMBL954666 0.85 KDM4E (0.64) KDM4EMAPK10HSD17B10SMN1; SMN2NPC1
SCHEMBL951202 0.85 FLT3 (0.67) KDM4EMAPK10HSD17B10SMN1; SMN2NPC1
SCHEMBL8373049 0.85 SMN1; SMN2 (0.63) KDM4EMAPK10HSD17B10SMN1; SMN2NPC1
SCHEMBL22308394 0.83 KDM4E (0.61) KDM4EMAPK10HSD17B10FLT1KDR
SCHEMBL4788248 0.82 KDM4E (0.57) KDM4EMAPK10HSD17B10SMN1; SMN2NPC1
SCHEMBL7846799 0.82 SMN1; SMN2 (0.60) KDM4EMAPK10HSD17B10SMN1; SMN2NPC1
SCHEMBL954391 0.81 KDM4E (1.00) KDM4EMAPK10HSD17B10SMN1; SMN2NPC1
SCHEMBL958960 0.80 KDM4E (0.64) KDM4EMAPK10HSD17B10SMN1; SMN2NPC1
SCHEMBL30026349 0.80 FLT3 (0.81) YTHDC1CCNA2CDK2FLT3CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110021467-A1 INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA SANOFI-AVENTIS (FR) 2011-01-27 US disclosed
US-7842711-B2 Indazolecarboxamide derivatives for the treatment and prevention of malaria SANOFI-AVENTIS (FR) 2010-11-30 US disclosed
US-20070185187-A1 INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
CN-1933834-A Use of indazolecarboxamide derivatives for the preparation of a medicament for the treatment and prevention of malaria SANOFI AVENTIS (FR) 2007-03-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185187-A1 INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA CYP3A43, CYP3A5, SIRT5 KDM4E 2696/4885MAPK10 4530/4885HSD17B10 1224/4885
US-20110021467-A1 INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA CYP3A43, CYP3A5, SIRT5 KDM4E 2696/4885MAPK10 4530/4885HSD17B10 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.